U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H13NO3.C4H11NO3
Molecular Weight 376.4037
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETOROLAC TROMETHAMINE

SMILES

NC(CO)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C3=CC=CC=C3

InChI

InChIKey=BWHLPLXXIDYSNW-UHFFFAOYSA-N
InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

HIDE SMILES / InChI
Molecular Formula C15H13NO3
Molecular Weight 255.2686
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula C4H11NO3
Molecular Weight 121.135
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ketorolac is a pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is an NSAID and is used principally for its analgesic activity and has been shown to decrease opioid requirements in post-operative patients. It does not affect consciousness or respiration but does have effects on gastric mucosa, renal perfusion, and platelet function. Ketorolac tromethamine ophthalmic solution is sold under brand name acular LS and is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Ketorolac tromethamine is a racemic mixture of [-]S- and [ ]R-enantiomeric forms, with the S-form having analgesic activity. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medication. Analgesia is probably produced via a peripheral action in which blockade of pain impulse generation results from decreased prostaglandin activity.

CNS Activity

Originator

Approval Year

1989
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ACULAR LS

Approved Use

ACULAR LS ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2382.2 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf
30 mg single, intramuscular
dose: 30 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1805.8 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf
31.5 mg single, nasal
dose: 31.5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11152.8 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf
30 mg single, intramuscular
dose: 30 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7477.3 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf
31.5 mg single, nasal
dose: 31.5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf
30 mg single, intramuscular
dose: 30 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
5.24 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf
31.5 mg single, nasal
dose: 31.5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg single, intrathecal
Highest studied dose
Dose: 2 mg
Route: intrathecal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/12406536/
healthy, 18-50
Health Status: healthy
Age Group: 18-50
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12406536/
Sources:
https://pubmed.ncbi.nlm.nih.gov/12406536/
30 mg single, intramuscular
Highest studied dose
Dose: 30 mg
Route: intramuscular
Route: single
Dose: 30 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/17192497/
healthy, 19-45
Health Status: healthy
Age Group: 19-45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17192497/
Sources:
https://pubmed.ncbi.nlm.nih.gov/17192497/
30 mg single, intranasal
Highest studied dose
Dose: 30 mg
Route: intranasal
Route: single
Dose: 30 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/17192497/
healthy, 19-45
Health Status: healthy
Age Group: 19-45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17192497/
Sources:
https://pubmed.ncbi.nlm.nih.gov/17192497/
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Other AEs: Nausea, Constipation...
Other AEs:
Nausea (58%)
Constipation (29%)
Vomiting (28%)
Nasal passage irritation (24%)
Headache (24%)
Flatulence (23%)
Anemia (19%)
Tachycardia (14%)
Pruritis (11%)
Dizziness (6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
Other AEs: Anaemia, Thrombocytopenia...
Other AEs:
Anaemia (below serious, 7 patients)
Thrombocytopenia (below serious, 3 patients)
Hyponatraemia (below serious, 3 patients)
Hypokalaemia (below serious, 2 patients)
Leucopenia (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Other AEs: Hypercapnia, Thrombocytopenia...
Other AEs:
Hypercapnia (below serious, 12 patients)
Thrombocytopenia (below serious, 12 patients)
Leukocytosis (below serious, 38 patients)
Hypokalaemia (below serious, 20 patients)
Hyperkalaemia (below serious, 3 patients)
Hyponatraemia (below serious, 10 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
AEs

AEs

AESignificanceDosePopulation
Pruritis 11%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Tachycardia 14%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Anemia 19%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Flatulence 23%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Headache 24%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Nasal passage irritation 24%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Vomiting 28%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Constipation 29%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Nausea 58%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Dizziness 6%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
unhealthy, 51.7
Health Status: unhealthy
Age Group: 51.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19594851/
Leucopenia below serious, 1 patient
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
Hypokalaemia below serious, 2 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
Hyponatraemia below serious, 3 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
Thrombocytopenia below serious, 3 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
Anaemia below serious, 7 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765128
Hyponatraemia below serious, 10 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Hypercapnia below serious, 12 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Thrombocytopenia below serious, 12 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Hypokalaemia below serious, 20 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Hyperkalaemia below serious, 3 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Leukocytosis below serious, 38 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00765232
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OAT1
725

OAT3
747

OCTN2
71

UGT2B7
197
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
UGT2B7
210
 no [IC50 >1000 uM]
OAT1
730
 strong [IC50 0.653 uM]
OAT3
749
 strong
OCTN2
71
 weak [Ki 1530 uM]
PubMed

PubMed

TitleDatePubMed
Effect of ketorolac on renal function after donor nephrectomy.
2002-06
The influence of timing and route of administration of intravenous ketorolac on analgesia after hand surgery.
2002-06
Early hospital discharge for intravesical ureteroneocystostomy.
2002-06
Subjective and objective comparison of critical care pathways for open donor nephrectomy.
2002-06
Novel 4,5-diaryl-3-hydroxy-2(5H)-furanones as anti-oxidants and anti-inflammatory agents.
2002-06
Children's use of PCA following spinal fusion.
2002-05-25
Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.
2002-05-24
Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery.
2002-05
Protective role of cyclooxygenase (COX) inhibitors in burn-induced intestinal and liver damage.
2002-05
Low-dose ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents.
2002-05
The role of spinal neuropeptides and prostaglandins in opioid physical dependence.
2002-05
Effect of topical diclofenac and ketorolac on patient discomfort and corneal sensitivity.
2002-04-06
Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial.
2002-04-06
Effect of 10 pharmacologic probes on mRNA levels of inducible nitric oxide synthetase and selected inflammatory cytokines in a rat model of acute otitis media.
2002-04
Ketorolac-based analgesia improves outcomes for living kidney donors.
2002-03-15
Intra-muscular ketorolac administered as a supplemental analgesic for removal of impacted third molar teeth: a prospective study.
2002-03
Parenteral ketorolac and risk of myocardial infarction.
2002-03
Effects of intravenous ketorolac and fentanyl combined with midazolam on analgesia and side effects during extracorporeal shock wave lithotripsy.
2002-03
Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery.
2002-03
Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain.
2002-03
Ketorolac for pain management after abdominal surgical procedures in infants.
2002-03
Treatment patterns of isolated benign headache in US emergency departments.
2002-03
Efficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting after laparoscopic cholecystectomy with sevoflurane and remifentanil infusion anaesthesia.
2002-02-28
Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.
2002-02
Drug-induced extrapyramidal reactions.
2002-02
Postoperative pain management: morphine versus ketorolac.
2002-02
Is the administration of ketorolac associated with preemptive analgesia?
2002-02
Preemptive analgesic effect or short delay for inflammation?
2002-02
Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients.
2002-02
Opioid-free analgesia following total knee arthroplasty--a multimodal approach using continuous lumbar plexus (psoas compartment) block, acetaminophen, and ketorolac.
2002-01-19
Multimodal analgesia and intravenous nutrition preserves total body protein following major upper gastrointestinal surgery.
2002-01-19
Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects.
2002-01
A systematic review of adjuncts for intravenous regional anesthesia for surgical procedures.
2002-01
Epidural hematoma after outpatient epidural anesthesia.
2002-01
Chiral pharmacokinetics of ketorolac in sheep after intravenous and intramuscular administration of the racemate.
2001-12
[Aortic stent: the anesthesiologist's point of view].
2001-12
Delayed diffuse lamellar keratitis after laser in situ keratomileusis.
2001-12
Topical ketorolac after cataract surgery.
2001-12
Analgesia and COX-2 inhibition.
2001-11-07
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001-11
Opioid analgesics versus ketorolac in spine and joint procedures: impact on healthcare resources.
2001-11
Pain control after knee arthroplasty: intraarticular versus epidural anesthesia.
2001-11
The effect of ketorolac and sevoflurane anesthesia on renal glomerular and tubular function.
2001-11
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
2001-10
Goal oriented general anesthesia for Cesarean section in a parturient with a large intracranial epidermoid cyst.
2001-10
Ketorolac vs tramadol in the treatment of postoperative pain during maxillofacial surgery.
2001-09
New advances in the treatment of sickle cell disease: focus on perioperative significance.
2001-08
Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.
2001
Single-dose dipyrone for acute postoperative pain.
2001
Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry.
2001
Patents

Patents

04089969
3
JP2002528495A
37
JP2003507415A
33
JP2006500085A
2
JP2009525778A
32
JP2011524366A
2
JP2966094B2
2
JP4756823B2
22

Sample Use Guides

In Vivo Use Guide
The recommended dose of ACULAR LS (ketorolac tromethamine ophthalmic solution) is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
Route of Administration: Other
In Vitro Use Guide
It was discovered, that ketorolac inhibition of stretch-induced ureteral contractility was concentration-dependent between 1 nM and 1 microM. Local administration of ketorolac at these doses may be useful during the management of stones while at the same time limiting the risk for adverse effects. Porcine ureter strips attached to force displacement transducers were suspended in organ tissue baths that contained aerated Krebs buffer. Tissues equilibrated for 1 hour, and a spontaneous contractility rate was established. Tissues were incubated with a concentration-response curve of ketorolac (0.1 nM-10 microM) for 90 minutes and compared with indomethacin (1 muM) and dimethyl sulfoxide (DMSO) 0.1%. Contractility rates were recorded on a polygraph and analyzed for changes over exposure time
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:02:59 GMT 2025
Edited
by admin
on Mon Mar 31 18:02:59 GMT 2025
Record UNII
4EVE5946BQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KETOROLAC TROMETAMOL
EP   MART.  
Preferred Name English
KETOROLAC TROMETHAMINE
ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
OMIDRIA COMPONENT KETOROLAC TROMETHAMINE
Brand Name English
(±)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)
Common Name English
LIXIDOL
Brand Name English
KETOROLAC TROMETAMOL [JAN]
Common Name English
KETOROLAC TROMETHAMINE [USP MONOGRAPH]
Common Name English
ACULAR
Brand Name English
ACUVAIL
Brand Name English
TARASYN
Brand Name English
2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL (1RS)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLATE
Systematic Name English
NSC-758637
Code English
KETOROLAC TROMETHAMINE [USP-RS]
Common Name English
1H-PYRROLIZINE-1-1H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO, (±)-, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)
Common Name English
Ketorolac tromethamine [WHO-DD]
Common Name English
KETOROLAC TROMETHAMINE [USAN]
Common Name English
DOLAC
Brand Name English
KETOROLAC (±)-FORM TROMETHAMINE SALT [MI]
Common Name English
KETOROLAC TROMETHAMINE [VANDF]
Common Name English
TORADOL
Brand Name English
KETOROLAC TROMETHAMINE [ORANGE BOOK]
Common Name English
SPRIX
Brand Name English
KETOROLAC TROMETAMOL [EP MONOGRAPH]
Common Name English
KETOROLAC TROMETAMOL [MART.]
Common Name English
2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL; 5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C61798
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
EVMPD
SUB02835MIG
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
PUBCHEM
84003
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
FDA UNII
4EVE5946BQ
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
ChEMBL
CHEMBL469
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
EPA CompTox
DTXSID0045597
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
USAN
T-104
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
RS_ITEM_NUM
1356665
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
CHEBI
6130
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
DRUG BANK
DBSALT001045
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
CAS
74103-07-4
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
SMS_ID
100000091653
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
RXCUI
28200
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY RxNorm
MESH
D020911
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
DAILYMED
4EVE5946BQ
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
MERCK INDEX
m6623
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY Merck Index
NSC
758637
Created by admin on Mon Mar 31 18:02:59 GMT 2025 , Edited by admin on Mon Mar 31 18:02:59 GMT 2025
PRIMARY
Related Record Type Details
Structure of KETOROLAC
PARENT -> SALT/SOLVATE
Structure of KETOROLAC TROMETHAMINE, (R)-
ENANTIOMER -> RACEMATE
Structure of KETOROLAC TROMETHAMINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of KETOROLAC TROMETHAMINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of KETOROLAC TROMETHAMINE, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of 5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZIN-1-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZIN-1-OL, (±)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1H-PYRROLIZINE-1-CARBOXAMIDE, 5-BENZOYL-2,3-DIHYDRO-N-(2-HYDROXY-1,1-BIS(HYDROXYMETHYL)ETHYL)-, (±)-
IMPURITY -> PARENT
Structure of KETOROLAC ETHYL ESTER
IMPURITY -> PARENT
unspecified
UNKNOWN
EP
Structure of 5-BENZOYL-1-METHOXY-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID, (±)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL 5-BENZOYL-1-HYDROXY2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLATE, (±)-
IMPURITY -> PARENT
unspecified
UNKNOWN
EP
Structure of 5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZIN-1-OL, (±)-
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.67
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZIN-1-ONE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.52
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID, (±)-
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 7-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID, (±)-
IMPURITY -> PARENT
unspecified
UNKNOWN
EP
Structure of PHENYL(2,3-DIHYDRO-1H-PYRROLIZIN-5-YL)METHANONE
IMPURITY -> PARENT
unspecified
UNKNOWN
EP
Structure of KETOROLAC METHYL ESTER
IMPURITY -> PARENT
unspecified
UNKNOWN
EP
Related Record Type Details
Structure of KETOROLAC
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966